


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



On JULY 29, 2004
TOWNSEND and TOWNSEND and CREW LLP
By: Kimberly Rose

PATENT
Attorney Docket No.: 018781-002730US
Client Reference No.: T99-008-3/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Lawrence R. McGee, et al.

Application No.: 10/810,325

Filed: March 25, 2004

For: COMPOUNDS FOR THE
MODULATION OF PPARY ACTIVITY

Examiner: To Be Assigned

Art Unit: 1614

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 10/209,905, filed March 25, 2004 (Attorney Docket No. 018781-002720US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicants would also like to bring to the attention of the Examiner the following related patent applications: U.S. Patent Application No. 09/847,887, filed May 2, 2001, publication no. 2002-0037928 (TTC Docket--5410); U.S. Patent Application No. 10/123,298, filed April 15, 2002, publication no. 2003-0088103 (TTC Docket--2130); U.S. Patent Application No. 09/741,415, filed December 19, 2000, now U.S. Patent No. 6,620,827, publication no. 2001-0027200 (TTC Docket-2120); and U.S. Patent Application No. 09/234,327, filed January 20, 1999, now U.S. Patent No. 6,200,995 (TTC Docket-2110). The Examiner is requested to make these documents of record in the subject application.

Applicants would also particularly like to bring to the attention of the Examiner the following related, co-pending applications, copies of which were submitted in the parent application. Applicants note for the Examiner that certain compounds are disclosed in the present application and in the 10/278,851 application, filed October 21, 2002, (cited as Reference No. 54 in the present IDS) that are the result of a collaborative effort between the present assignee and the co-assignee of the 10/278,851 application. Those compounds are not specifically claimed herein, but were the subject of claims presented in the 10/278,851 application and its continuation, U.S. Patent Application No. 10/719,997. Additionally, certain species of compounds are recited in the combination pharmaceutical composition claims in Provisional Application No. 60/201,613, filed May 3, 2003 (cited as Reference No. 56 in the present IDS). Provisional Application No. 60/201,613 is a priority application for U.S. Application No. 10/456,932, filed June 5, 2003 (cited as Reference No. 55 in the present IDS).


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
FJM:jvl
60206413 v1




Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known	
			Application Number	10/810,325
			Filing Date	March 25, 2004
			First Named Inventor	McGee, Lawrence R.
			Art Unit	1614
Examiner Name	To Be Assigned			
Sheet	1	of	Attorney Docket Number	018781-002730US

U.S. PATENT DOCUMENTS*				
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	1.	2,407,309	09-10-1946	Lott, et al.
	2.	3,034,955	05-15-1962	Frick, et al.
	3.	3,674,843	07-04-1972	Shen, et al.
	4.	3,686,192	08-22-1972	Moore, et al.
	5.	4,003,734	01-18-1977	Johnston
	6.	4,013,621	03-22-1977	Knell
	7.	4,061,642	12-06-1977	Fleckenstein, et al.
	8.	4,218,237	08-19-1980	Nishiyama, et al.
	9.	4,289,876	09-15-1981	Algieri et al.
	10.	4,499,304	02-12-1985	Gabrielsen, et al.
	11.	4,549,901	10-29-1985	James
	12.	4,565,568	01-21-1986	Johnston et al.
	13.	4,577,028	03-18-1986	Martin et al.
	14.	4,670,045	06-02-1987	Ehr et al.
	15.	4,731,090	03-15-1988	Boger, et al.
	16.	4,756,739	07-12-1988	Fuss, et al.
	17.	4,851,419	07-25-1989	Cox
	18.	4,866,079	09-12-1989	Boger et al.
	19.	4,900,751	02-13-1990	Cox
	20.	4,946,854	08-07-1990	Maienfisch et al.
	21.	4,952,235	08-28-1990	Andree et al.
	22.	4,987,141	01-22-1991	Bushell, et al.
	23.	5,008,276	04-16-1991	Clough, et al.
	24.	5,070,096	12-03-1991	Mohrs et al.
	25.	5,093,340	03-03-1992	Mohrs et al.
	26.	5,143,937	09-01-1992	Lang, et al.
	27.	5,151,428	09-29-1992	Sakamoto et al.
	28.	5,202,336	04-13-1993	Mohrs et al.
	29.	5,250,549	10-05-1993	Yoshino et al.
	30.	5,304,532	04-19-1994	Munro et al.
	31.	5,360,810	11-01-1994	Hayase et al.
	32.	5,444,036	08-22-1995	Iwasaki et al.
	33.	5,514,696	05-07-1996	Murugesan et al.
	34.	5,545,669	08-13-1996	Adams, et al.
	35.	5,610,320	03-11-1997	Yoshino, et al.
	36.	5,624,937	04-29-1997	Reel
	37.	5,643,914	07-01-1997	Daines
	38.	5,684,195	11-04-1997	Huang, et al.
	39.	5,716,993	02-10-1998	Ozaki et al.
	40.	5,780,483	07-14-1998	Widdowson et al.
	41.	5,814,646	09-29-1998	Heinz

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known	
			Application Number	10/810,325
			Filing Date	March 25, 2004
			First Named Inventor	McGee, Lawrence R.
			Art Unit	1614
Examiner Name	To Be Assigned			
Sheet	2	of	Attorney Docket Number	018781-002730US

U.S. PATENT DOCUMENTS+				
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	42.	5,880,136	03-09-1999	Duggan, et al.
	43.	5,990,126	11-23-1999	Park et al.
	44.	6,028,052	02-22-2000	Heyman et al.
	45.	6,200,995 B1	03-03-2001	De la Brouse-Elwood
	46.	6,294,559	09-25-2001	Smith
	47.	6,353,011	03-05-2002	Pershadsingh et al.
	48.	6,369,075 B1	04-09-2002	Ruggeri et al.
	49.	6,583,157	06-24-2003	McGee et al.
	50.	6,620,827	09-16-2003	De la Brouse-Elwood et al.
	51.	6,653,332	11-25-2003	Jaen et al.
	52.	2001/0028200	10-11-2001	Hwang et al.
	53.	2003/0088103	05-08-2003	Houze et al.
	54.	2003/0171399	09-11-2003	McGee et al.
	55.	USSN 10/456,932	N/A (Filed 06/05/2003)	Jaen et al.
	56.	USSN 60/201,613	N/A (Filed 05/03/2000)	Jaen et al.

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)		
	57.	CH	592 411	10-31-1977	CIBA GEIGY AG
	58.	DE	3632329	A1 03-31-1988	Bayer AG
	59.	EP	0 069 585	A1 01-12-1983	Eastman Kodak
	60.	EP	0 148 730	A2 07-17-1985	CIBA GEIGY AG (CH)
	61.	EP	0 261 539	A2 03-30-1988	Bayer AG
	62.	EP	0 306 222	A2 03-08-1989	Hokko Chemical Ind.
	63.	EP	0 472 053	B1 06-17-1998	Esai Co., Ltd.
	64.	EP	0 749 751	A2 12-27-1996	Takeda Chemical Industries
	65.	EP	0 778 267	A1 11-06-1996	OTSUKA KAGAKU KK
	66.	EP	0 855 391	A1 07-29-1998	Snow Brand Milk Prod
	67.	JP	55-79369	A1 06-14-1980	
	68.	JP	64-6245	A1 01-10-1989	
	69.	WO	95/01326	A1 01-12-1995	Wellcome Found
	70.	WO	95/33461	A1 12-14-1995	SmithKline Beecham
	71.	WO	99/50237	A1 10-07-1999	Hiroyoshi Hidaka

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/810,325	
(use as many sheets as necessary)			Filing Date	March 25, 2004	
			First Named Inventor	McGee, Lawrence R.	
			Art Unit	1614	
			Examiner Name	To Be Assigned	
Sheet	3	of	Attorney Docket Number	018781-002730US	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴			
72.	WO	96/15118	A1	05-23-1996	Thomas Andrew Peter	<input type="checkbox"/>
73.	WO	97/00857	A1	01-09-1997	MASSACHUSETTS INST TECHNOLOGY	<input type="checkbox"/>
74.	WO	97/30677	A1	08-28-1997	Tularik Inc.	<input type="checkbox"/>
75.	WO	97/31907	A1	09-04-1997	CALLAGHAN JOHN MARK O	<input type="checkbox"/>
76.	WO	97/36579	A1	10-09-1997	GLAXO GROUP LTD	<input type="checkbox"/>
77.	WO	99/06378	A1	02-11-1999	BRIDGES ALEXANDER JAMES	<input type="checkbox"/>
78.	WO	99/10320	A1	03-04-1999	Tularik Inc.	<input type="checkbox"/>
79.	WO	99/38845	A1	08-05-1999	Tularik Inc.	<input type="checkbox"/>
80.	WO	01/00579	A1	01-04-2001	Japan Tobacco Inc.	<input type="checkbox"/>
81.	WO	01/60807	A1	08-23-2001	Merck & Co.	<input type="checkbox"/>
82.	WO	01/70723	A1	09-27-2001	Mitsui Chem., Inc.	<input type="checkbox"/>
83.	WO	01/83427	A1	11-08-2001	Sankyo Co. Ltd.	<input type="checkbox"/>
84.	WO	01/87860	A2	11-22-2002	Ortho-McNeil Pharmaceutical, Inc.	<input type="checkbox"/>
85.	WO	01/87861	A2	11-22-2001	Ortho-McNeil Pharmaceutical, Inc.	<input type="checkbox"/>
86.	WO	01/87862	A2	11-22-2002	Ortho-McNeil Pharmaceutical, Inc.	<input type="checkbox"/>
87.	WO	01/95906	A1	12-20-2001	SmithKline Beecham	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST-3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

60206413 v1

Substitute for form 1449B/PTC				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	4	of			
			Attorney Docket Number		
			018781-002730US		

NON PATENT LITERATURE DOCUMENTS				Complete if Known	
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	88.	BADILESCU, I., "Synthesis of some N-aryl- and N,N-dialkyl-p-chloro-benzensulfonamides" REV.CHIM., vol. 17, no. 11, 1966, pages 705-6 & Chemical Abstracts, vol. 67, no. 9, August 28, 1967, Columbus, Ohio, United States; abstract no. 43516y, page 4076; XP002099084			
	89.	BAGULEY et al., Database accession no. 108:179602, Database Chemabs 'Online!, RN 106831-10-1 CAPLUS, Eur. J. Cancer Clin. Oncol., 24(2):205-210 (1988)			
	90.	BURMISTROV et al., Database accession no. 115:8165, Database Chemabs 'Online!, RNs 98187-76-9 CAPLUS, 134284-40-5 CAPLUS, Zh. Org. Khim, 26(9):1995-1998 (1990)			
	91.	BURMISTROV et al., Database accession no. 122:132338, Database Chemabs 'Online!, RN 134284-40-5 CAPLUS, Zh. Org. Khim, 30(5):744-747 (1994)			
	92.	CAIN et al., "Potential antitumor agents. 14. Acridylmethanesulfonanilides," J. Med. Chem. 17(9):922-930 (1974)			
	93.	CHATURVEDI et al., "Antibacterial studies of 7-(α -substituted sulfonamido)methyl- and 7-(α -substituted sulfonamido)phenyl-8-hydroxyquinolines," Journal of the Indian Chemical Society 61(2):175-176 (1984) (Abstract. Chem. Abstract Accession Number: 101:87311).			
	94.	COLLINS, J. et al., "N-(2-Benzoylphenyl)-L-tyrosine PPAR γ agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety" J. Med. Chem. 41(25):5037-5054 (1998).			
	95.	DENNY et al., Database accession no. 96:79437, Database Chemabs 'Online!, RNs 80260-24-8 CAPLUS, 80260-26-0 CAPLUS, J. Med. Chem., 25(3):276-315 (1982)			
	96.	DUMAS et al., "Synthesis and structure-activity relationships of novel small molecule cathepsin D inhibitors," Bioorg. Med. Chem. Lett. 9(17):2531-2536 (1999) (Abstract. Chem. Abstract Accession Number: 131:336969)			
	97.	FORMAN et al., "15-Deoxy- $\Delta^{12,14}$ -Prostaglandin J ₂ Is a Ligand for the Adipocyte Determination Factor PPAR γ ," Cell, 83:803-812 (1995)			
	98.	JIANG et al., "PPAR- γ agonists inhibit production of monocyte inflammatory cytokines," Nature, Vol. 391, pp. 82-86, (January 1998).			
	99.	LEHMANN et al., "Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs," The Journal of Biological Chemistry, 272(6):3406-3410 (1997)			
	100.	LEHMANN, J., et al., "An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPAR γ)," J. Bio. Chem. 270(22): 12953-12956 (1995).			
	101.	MYSYK et al., Database accession no. 92:163637, Database Chemabs 'Online!, RN 73320-75-9 CAPLUS, Zh. Org. Khim, 15(12):2499-2502 (1979)			
	102.	PIEPER et al., Database accession no. 112:138679, Database Chemabs 'Online!, RN 101513-48-8 CAPLUS, Arzneim.-Forsch., 39(9):1073-1080 (1989)			
	103.	RICOTE et al., "The peroxisome proliferator-activated receptor- γ is a negative regulator of macrophage activation," Nature, Vol. 391, pp. 79-82, (January 1998).			

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	To Be Assigned
<i>(use as many sheets as necessary)</i>				<i>Filing Date</i>	March 25, 2004
				<i>First Named Inventor</i>	McGee, Lawrence R.
				<i>Art Unit</i>	To Be Assigned
				<i>Examiner Name</i>	To Be Assigned
Sheet	5	of		<i>Attorney Docket Number</i>	018781-002730US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	104.	SARUL, et al., Database accession no. 103:123106, Database Chemabs 'Online!', RN 98187-77-0 CAPLUS, Latv. Psr Zinat. Akad. Vestis, Kim. Ser., 2:225-228 (1985)		
	105.	SEBE et al., Database accession no. 117:214517, Database Chemabs 'Online!', RNs 144206-02-0 CAPLUS, 144232-65-5 CAPLUS, Rev. Chim, 43(5-6):222-225 (1992)		
	106.	SPIEGELMAN B.M., "PPAR- γ : Adipogenic Regulator and Thiazolidinedione Receptor," Diabites, Vo. 47, pp. 507-514, (April 1998).		
	107.	WILSON et al., "The Structure-Activity Relationship between Peroxisome Proliferator-Activated Receptor γ Agonism and the Antihyperglycemic Activity of Thiazolidinediones," J. Med. Chem., 39:665-668 (1996)		
	108.	WINDHOLZ et al. (Eds.), The Merck Index, 10th Ed., Merck & Co., Inc., Rahway, NJ., pp. 849-850, Abstract 5792 (1983).		
	109.	WOLLWEBER et al., Database accession no. 101:151540, Database Chemabs 'Online!', RN 92114-63-1 CAPLUS, Arzneim.-Forsch., 34(5):531-542 (1984)		
	110.	ZAITSEVA et al., Database accession no. 86:43377, Database Chemabs 'Online!', RN 61381-98-4 CAPLUS, Zh. Org. Khim, 12(9):1987-1992 (1976)		

60206413 v1

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.